ClinicalTrials.gg
TerminatedNCT01400893Updated Apr 27, 2021Results posted

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

An interventional study of SCD in Acute Kidney Injury, sponsored by SeaStar Medical. Terminated at 26 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by SeaStar Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Enrollment
82nd of 237
134 · median 67
Started
2011
with 9 others
No phase
106 of 370
25 open now
Registered
64th of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 82nd largest by enrollment of the 237 interventional ones that give a count, is one of 10 that started in 2011, is one of 106 with no phase, and was the 64th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).

Read the detailed description

Acute kidney injury is a condition where the kidneys are not capable of producing adequate urine. Therefore, another way to remove waste from the body is needed to hopefully allow time for the kidneys to heal. One method of removing waste from the body is called Continuous Renal Replacement Therapy (CRRT) or variations of that therapy. This study will evaluate the safety of the device while it is connected to the CRRT tubing for up to 7 days. Patients will be followed up until day 60 following the treatment.

03

Conditions studied

  • Acute Kidney Injury

Keywords

  • Acute Renal Failure
  • Acute kidney injury
  • Acute tubular necrosis
  • Continuous Renal Replacement Therapy
  • Severe sepsis
  • Selective cytopheretic device
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A patient, or legal representative, has signed a written form.
  2. Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma).
  3. Age 18 to 80 years.
  4. Females of child bearing potential who are not pregnant (confirmed by a negative serum pregnancy test) and not lactating if recently post-partum.
  5. Must be receiving and tolerating CRRT therapy for a minimum of 4 hours, but not longer than 24.
  6. Expected to remain in the ICU for at least 96 hours after evaluation for enrollment.
  7. A clinical diagnosis of ATN due to hemodynamic or toxic etiologies. ATN is defined as Acute Kidney Injury occurring in a setting of acute ischemic or nephrotoxic injury with oliguria (average \<20 mL/hr) for >6-12 hours or: an increase in serum creatinine ≥2 mg/dL (≥1.5 mg/dL in females) over a period of ≤4 days. (Note: Prerenal, hepatorenal, vascular, interstitial, glomerular, and obstructive etiologies are excluded on clinical or other diagnostic grounds.)
  8. Presence of at least one non-renal organ failure or present sepsis as defined in Appendix C.
  9. All patients must be able to tolerate regional citrate anticoagulation.

Exclusion criteria

Exclusion Criteria:

  1. Irreversible brain damage based on available historical and clinical information.
  2. Presence of any organ transplant at any time.
  3. Acute or chronic use of circulatory support device such as LVADs, RVADs, BIVADs, ECMO.
  4. Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal replacement therapy prior to this episode of acute kidney injury.
  5. AKI occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP), malignant hypertension, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, hepatorenal syndrome, cyclosporine or tacrolimus nephrotoxicity.
  6. which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three month period after study therapy.
  7. Chronic (e.g., /AIDS, chronic therapy >20 mg/day prednisone equivalent on a chronic basis). The acute use of glucocorticoids is permissible.
  8. Severe liver failure as documented by a Liver Failure Score >12 (see Appendix F).
  9. Currently in Do Not Resuscitate (DNR) status or DNR status anticipated within the next 7 days.
  10. Currently in Comfort measures Only or Comfort Measures Only status anticipated within next 7 days.
  11. Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
  12. Patient not expected to survive 28 days because of an irreversible medical condition. (This is not restrictive to AKI, and may include situations such as the presence of irreversible brain damage, untreatable malignancy, inoperable life threatening condition, or any condition to which therapy is regarded as futile by the PI.)
  13. Any medical condition that the Investigator thinks may interfere with the study objectives.
  14. Physician refusal.
  15. Patient is a prisoner.
  16. Dry weight of >150 kg.
  17. More than one hemodialysis treatment during this hospital admission or prior to transfer from an outside hospital.
  18. count \<30,000/mm3 at time of screening.
  19. Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where only measurements and/or samples are taken (NO TEST DEVICE OR TEST DRUG USED) are allowed to participate.
  20. Use of any other drug or device within the previous 30 days.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    CRRT + SCD

    Patients with a diagnosis of AKI requires CRRT will be randomized

    Device: SCD

  • No intervention
    CRRT alone

    Patients with a diagnosis of AKI requires CRRT will be randomized

Interventions

  • DeviceSCD

    The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.

06

What researchers measure

Primary outcomes

  1. The Primary Clinical Efficacy Endpoint in This Trial is All Cause Mortality Through 60 Days Post-randomization.

    All cause mortality through day 60 post-randomization. The outcome data reported here describe the mortality at Day 60 (primary endpoint) of the treated subjects which received the recommended ionized calcium (riCa) for ≥ 90% of treatment time.

    Time frame: Day 60 following treatment initiation

Secondary outcomes

  1. Renal Replacement Therapy Dependency at Day 60.

    RRT dependency at day 60 is defined as patient not receiving any form of intermittent or continuous renal replacement therapy at 60 days post enrollment in the study with no plans for additional intermittent or continuous renal replacement therapy.

    Time frame: Day 60 following treatment initiation

07

Results

Posted Aug 29, 2017

Participant flow

Participant flow — Overall Study
MilestoneCRRT + SCDCRRT Alone
Started6965
Completed4238
Not completed2727
Withdrew: Death2721
Withdrew: Lost to follow-up06

Outcome measures

PrimaryThe Primary Clinical Efficacy Endpoint in This Trial is All Cause Mortality Through 60 Days Post-randomization.

All cause mortality through day 60 post-randomization. The outcome data reported here describe the mortality at Day 60 (primary endpoint) of the treated subjects which received the recommended ionized calcium (riCa) for ≥ 90% of treatment time.

Time frame:
Day 60 following treatment initiation
Reported as:
Count of participants · Participants
The Primary Clinical Efficacy Endpoint in This Trial is All Cause Mortality Through 60 Days Post-randomization.
ParticipantsCRRT + SCDCRRT Alone
Alive1616
Dead311
SecondaryRenal Replacement Therapy Dependency at Day 60.

RRT dependency at day 60 is defined as patient not receiving any form of intermittent or continuous renal replacement therapy at 60 days post enrollment in the study with no plans for additional intermittent or continuous renal replacement therapy.

Time frame:
Day 60 following treatment initiation
Reported as:
Count of participants · Participants
Renal Replacement Therapy Dependency at Day 60.
ParticipantsCRRT + SCDCRRT Alone
Renal Replacement Therapy Dependency at Day 60.315

Adverse events

Collected over Up to 7 days of SCD treatment or control. This time frame differs from the primary outcome measure of 60 day mortality since therapy was provided up to 7 days of SCD treatment. The adverse events were captured only during SCD treatment times since device related events would occur at that time frame. ITT patients are included in this table.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CRRT + SCD27/69 (39.1%)45/69 (65.2%)—
CRRT Alone21/59 (35.6%)40/63 (63.5%)—
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCRRT + SCDCRRT Alone
Cardiac disordersCardiac disorders12/6910/63
Infections and infestationsInfections and infestations12/6910/63
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders10/6910/63
Blood and lymphatic system disordersBlood and lymphatic system disorders8/693/63
General disorders and administration site conditionsGeneral disorders4/697/63
Vascular disordersVascular disorders7/694/63
Gastrointestinal disordersGastrointestinal disorders4/696/63
Renal and urinary disordersRenal and urinary disorders1/693/63
Metabolism and nutrition disordersMetabolism and nutrition disorders2/692/63
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders0/692/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)CRRT + SCDCRRT AloneTotal
Mean57.2 ± 13.153.5 ± 14.755.4 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)CRRT + SCDCRRT AloneTotal
Female272552
Male424082
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CRRT + SCDCRRT AloneTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American151429
White5348101
More than one race123
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)CRRT + SCDCRRT AloneTotal
United States6965134
08

Study locations

26 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • UCLA
    Los Angeles, California 90025, United States
  • University of California, San Diego
    San Diego, California 92103, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • University of Florida
    Jacksonville, Florida 32209, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Isreal Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • University of Mississippi
    Jackson, Mississippi 39216, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Sanford Health
    Fargo, North Dakota 58122, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Medical University Of South Carolina
    Charleston, South Carolina 29425, United States
  • Memorial Hospital
    Chattanooga, Tennessee 37403, United States
  • Erlanger Hospital
    Chattanooga, Tennessee 37404, United States
  • Dallas VA Medical Center
    Dallas, Texas 75216, United States
  • University of Texas
    Houston, Texas 77030, United States
  • INOVA Health Care Services
    Falls Church, Virginia 22042, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Tumlin JA, Galphin CM, Tolwani AJ, Chan MR, Vijayan A, Finkel K, Szamosfalvi B, Dev D, DaSilva JR, Astor BC, Yevzlin AS, Humes HD; SCD Investigator Group. A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury. PLoS One. 2015 Aug 5;10(8):e0132482. doi: 10.1371/journal.pone.0132482. eCollection 2015. PubMed 26244978 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2011
First posted
Jul 25, 2011
Start
Aug 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Aug 29, 2017
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01400893
Lead sponsor
SeaStar Medical
Responsible party
Sponsor
First posted
Jul 25, 2011
Start date
Aug 2011
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Aug 29, 2017
Last update
Apr 27, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion